Latest Lead News

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

Elevate Uranium has expanded its global uranium resource base to 169 million pounds of U3O8 through the strategic acquisition of the Napperby Uranium Project and complementary assets from Core Lithium. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.

Elevate Uranium Ltd has expanded its global uranium resource to 169 million pounds of U3O8 through the acquisition of the Napperby Uranium Project and complementary assets from Core Lithium Ltd. This move consolidates its Central Australian portfolio and leverages its proprietary U-pgrade™ beneficiation technology.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.

AusQuest Limited’s recent reconnaissance drilling at its Mt Davis Project in Western Australia has revealed promising lead, copper, and silver anomalies, suggesting potential for sediment-hosted base metal deposits.

CPP Investments and Goodman Group have launched a A$14 billion partnership to develop data centres across key European markets, marking CPP’s first foray into European digital infrastructure.

VRX Silica Limited has announced a strategic leadership transition with Tony Swiericzuk appointed as CEO, succeeding Bruce Maluish who will step down in 2026 but remain on the board. This move positions VRX to advance its Arrowsmith North silica sand project towards production.

Saluda Medical has received CE certification for its EVA™ Sensing Technology, enabling commercialisation in Europe and recognition in Australia following prior FDA approval. This milestone sets the stage for a broader rollout of its personalised spinal cord stimulation therapy in early 2026.

Lithium Universe Limited has completed the second tranche of its share placement, raising $40,000 and issuing over 56 million listed options, as it pushes forward with lithium refinery projects in Québec and Texas.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.